phase 1 study - Robuta Search

https://www.prnewswire.com/news-releases/biotheryx-doses-first-patient-in-phase-1-study-investigating-lead-protein-degrader-candidate-btx-1188-301468224.html BioTheryX Doses First Patient in Phase 1 Study Investigating Lead Protein Degrader Candidate... /PRNewswire/ -- BioTheryX, Inc., a clinical-stage company focused on developing targeted protein degraders to create life-saving medicines, today announced... phase 1 study https://sciencedaily.com/releases/2021/02/210203123520.htm Intranasal influenza vaccine spurs strong immune response in Phase 1 study | ScienceDaily An experimental single-dose, intranasal influenza vaccine was safe and produced a durable immune response when tested in a Phase 1 study. The investigational... intranasal influenza vaccine phase 1 study immune response https://www.jnj.com/media-center/press-releases/updated-results-from-the-phase-1-study-of-the-bcmaxcd3-bispecific-teclistamab-show-preliminary-efficacy-in-patients-with-heavily-pretreated-relapsed-or-refractory-multiple-myeloma Updated Results from the Phase 1 Study of the BCMAxCD3 Bispecific Teclistamab Show Preliminary... Nov 16, 2025 - First-reported results for the subcutaneous formulation and updated results for the intravenous formulation presented at ASH 2020 phase 1 study https://www.biospace.com/gain-therapeutics-announces-the-completion-of-dosing-in-the-multiple-ascending-dose-mad-of-the-phase-1-study-of-gt-02287-a-novel-small-molecule-therapy-for-parkinsons-disease Gain Therapeutics Announces the Completion of Dosing of the Phase 1 Study of GT-02287 - BioSpace phase 1 study https://www.biospace.com/phaxiam-therapeutics-obtains-authorizations-to-launch-its-phase-1-study-in-endocarditis-infections-caused-by-staphylococcus-aureus PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections... phase 1 study https://www.businesswire.com/news/home/20241030626999/en/Alterome-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Study-of-ALTA2618-in-AKT1-E17K-mutant-solid-tumors-AKTive-001 Alterome Therapeutics Announces First Patient Dosed in Phase 1 Study of ALTA2618 in AKT1... Alterome Therapeutics, Inc., a clinical stage biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for ... phase 1 study https://www.biospace.com/tranquis-therapeutics-announces-initiation-of-phase-1-study-of-tqs-168 Tranquis Therapeutics Announces Initiation of Phase 1 Study of TQS-168 - BioSpace Dec 8, 2021 - Tranquis Therapeutics today announced the initiation of dosing in a Phase 1 clinical study of TQS-168 in healthy volunteers. phase 1 study therapeutics announces initiation https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1533467/full Frontiers | Updates from a single-center phase 2 study of PD-1 inhibitor combined with... IntroductionAnti-PD-1 monotherapy has shown limited clinical efficacy in patients with relapsed/refractory acute myeloid leukemia (r/r AML). Our study aimed ...